Avastin decreases PCV symptoms
June 13th 2008Intravitreal injections of bevacizumab (Avastin; Genentech) stabilize vision and decrease retinal detachment in patients with polypoidal choroidal vasculopathy (PCV), according to a study published in the May 2008 issue of the British Journal of Ophthalmology.
Combination therapies go head to head
June 6th 2008Azarga (brinzolamide 1%/timolol 0.5% eye drops suspension; Alcon) and Cosopt (dorzolamide 2%/timolol 0.5% eye drops solution; Merck) are equally efficacious in IOP-lowering capacity, however, Azarga offers greater ocular comfort, according to a study presented at this week?s European Glaucoma Society congress in Berlin, Germany.
OPTTX system offers hope to some wet AMD sufferers
June 4th 2008The OPTTX System (Novadaq Technologies) stabilizes or improves vision at one year in patients with wet age-related macular degeneration (AMD), many of who have failed previous therapies and have no other treatment alternatives, according to Professor Giovanni Staurenghi of Sacco Hospital, University of Milan, Italy, reporting at this year?s EURETINA congress in Vienna, Austria.
Lack of eye drop refrigeration a problem
June 1st 2008The inadequate refrigeration of chloramphenicol generics in India could be contributing to the evolution of resistant organisms and impacting the quality of Indian-made products available in Europe, according to a study published in the May 2008 issue of the British Journal of Ophthalmology.
First preservative-free prostaglandin treatment approved
June 1st 2008Taflotan (tafluprost; Santen Oy), a benzalkonium chloride (BAK)-free prostaglandin analogue for the treatment of glaucoma, has received marketing authorization in Denmark and Germany, making it the first preservative-free prostaglandin eye drop to be approved.